ERBB3 and colorectal carcinoma: Patritumab has shown promising anti-tumor effects in CRC [22] and breast cancer in-vitro and in-vivo cancer models, where it effectively blocked HER3 phosphorylation, degraded HER3, and decreased tumor burden [23–24].